| pubmed-article:792737 | pubmed:abstractText | A controlled clinical trial of the anti-inflammatory, analgesic, muscle-relaxing and anxiolytic activity of a new compound (parsalmide) was compared with that of phenybutazone in 40 patients with acute or exacerbated inflammatory or degenerative processes randomly distributed into two treatment groups. Parsalmide was more effective in the relief of joint swelling and anxiety and gave better motility. On an overall evaluation, however, it was on a par with phenylbutazone. Treatment had to be suspended in two cases treated with phenylbutasone, whereas tolerance was good with parsalmide and no suspensions were required. | lld:pubmed |
